Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127970 | 0.89 | HCAR2 (0.46) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL6973751 | 0.86 | ATM (0.46) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL130609 | 0.83 | ATM (0.65) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL128719 | 0.83 | ATM (0.65) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL6974764 | 0.81 | TDP1 (0.42) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL127528 | 0.81 | ATM (0.59) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL131584 | 0.81 | ATM (0.63) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL127141 | 0.81 | HCAR2 (0.42) | TSHRHCAR2ALDH1A1MAPTNPSR1 | |
| SCHEMBL27510969 | 0.80 | ATM (0.74) | ATMTSHRHPGDHCAR2ALDH1A1 | |
| SCHEMBL4740627 | 0.79 | ATM (0.61) | ATMTSHRHPGDHCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | ATM 3121/4885TSHR 1420/4885HPGD 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.